Inverse relationship between HBV DNA levels and liver histopathological changes in immune-tolerant CHB patients.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Blackwell Scientific Publications Country of Publication: England NLM ID: 9435672 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2893 (Electronic) Linking ISSN: 13520504 NLM ISO Abbreviation: J Viral Hepat Subsets: MEDLINE
    • Publication Information:
      Original Publication: Oxford ; Boston : Blackwell Scientific Publications, 1994-
    • Subject Terms:
    • Abstract:
      Limited data exist regarding the association between hepatitis B virus (HBV) DNA levels and liver histopathological changes in patients with chronic hepatitis B (CHB) during the immune tolerant (IT) phase. In this study, we retrospectively analysed liver biopsy results from 150 adult IT-CHB patients. The liver tissue necroinflammation and fibrosis were evaluated by the Scheuer scoring system. Multivariate logistic regression, smooth curve fitting, and segmented regression models were used to examine the association between HBV DNA levels and liver histopathological changes. A total of 26%, 30.67% and 42% of IT patients had significant necroinflammation (≥G2), significant fibrosis (≥S2) and significant histopathological changes (≥G2 and/or ≥S2), respectively. HBV DNA levels were independently and non-linear inversely associated with significant necroinflammation and histopathological changes in IT-CHB patients. Patients with HBV DNA levels <10 7  IU/mL had a higher risk of significant histopathological changes compared to those with levels >10 7  IU/mL. The findings were further confirmed by smooth curve fitting analyses, subgroup and sensitivity analyses. In segmented regression model analyses, the optimal DNA value for the lowest odds ratio of significant histopathological changes was 7.26 log10 IU/mL. A non-linear inverse association between HBV DNA levels and significant histopathological changes in IT-CHB patients. DNA 7.26 log10 IU/mL may serve as a potential cut-off point to define a 'true immune tolerant phase' with minimal liver histopathological changes.
      (© 2024 John Wiley & Sons Ltd.)
    • References:
      Lampertico P, Agarwal K, Berg T, et al. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370‐398. doi:10.1016/j.jhep.2017.03.021.
      Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560‐1599. doi:10.1002/hep.29800.
      Sarin SK, Kumar M, Lau GK, et al. Asian‐Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1‐98. doi:10.1007/s12072-015-9675-4.
      Razavi‐Shearer D, Gamkrelidze I, Nguyen MH, et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383‐403. doi:10.1016/S2468-1253(18)30056-6.
      Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261‐283. doi:10.1002/hep.28156.
      Lee HW, Kim EH, Lee J, et al. Natural history of untreated HBeAg‐positive chronic HBV infection with persistently elevated HBV DNA but Normal alanine aminotransferase. Clin Transl Gastroenterol. 2020;11(3):e00140. doi:10.14309/ctg.0000000000000140.
      Cornberg M, Lok ASF, Terrault NA, et al. 2019 EASL‐AASLD HBV treatment endpoints conference faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B–report from the 2019 EASL‐AASLD HBV treatment endpoints conference. J Hepatol. 2020;72(3):539‐557. doi:10.1016/j.jhep.2019.11.003.
      Lee HW, Chon YE, Kim BK, et al. Negligible HCC risk during stringently defined untreated immune‐tolerant phase of chronic hepatitis B. Eur J Intern Med. 2021;84:68‐73. doi:10.1016/j.ejim.2020.10.022.
      Lee HW, Kim SU, Baatarkhuu O, et al. Comparison between chronic hepatitis B patients with untreated immune‐tolerant phase vs. those with virological response by antivirals. Sci Rep. 2019;9(1):2508. doi:10.1038/s41598-019-39043-2.
      Kim GA, Lim YS, Han S, et al. High risk of hepatocellular carcinoma and death in patients with immune‐tolerant‐phase chronic hepatitis B. Gut. 2018;67(5):945‐952. doi:10.1136/gutjnl-2017-314904.
      Kim GA, Han S, Choi GH, Choi J, Lim YS. Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients. Aliment Pharmacol Ther. 2020;51(11):1169‐1179. doi:10.1111/apt.15725.
      Chen CF, Lee WC, Yang HI, et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology. 2011;141(4):1240‐1248. doi:10.1053/j.gastro.2011.06.036.
      Freeland C, Vader D, Cohen C, George B. A predictive model for hepatitis b infection among high‐risk adults using a community‐based sample in greater philadelphia. J Viral Hepat. 2020;27:1319‐1325. doi:10.1111/jvh.13365.
      Jo AJ, Choi WM, Kim HJ, et al. A risk scoring system to predict clinical events in chronic hepatitis B virus infection: a nationwide cohort study. J Viral Hepat. 2022;29:115‐123. doi:10.1111/jvh.13631.
      Yoo JJ, Park SY, Moon JE, et al. Long‐term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune‐tolerant phase. Clin Mol Hepatol. 2023;29:482‐495. doi:10.3350/cmh.2022.0322.
      Yang HI, Yuen MF, Chan HLY, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH‐B): development and validation of a predictive score. Lancet Oncol. 2011;12(6):568‐574. doi:10.1016/S1470-2045(11)70077-8.
      Xing YF, Zhou DQ, He JS. Clinical and histopathological features of chronic hepatitis B virus infected patients with high HBV‐DNA viral load and normal alanine aminotransferase level: a multicentre‐based study in China. PLoS One. 2018;13(9):e0203220. doi:10.1371/journal.pone.0203220.
      Zhang L, Bi X, Chen X, et al. A nomogram based on HBeAg, AST, and age to predict non‐minimal liver inflammation in CHB patients with ALT <80 U/L. Front Immunol. 2023;19(13):1119124. doi:10.3389/fimmu.2022.1119124.
      Teng J, Du Y, Visalath P, et al. A noninvasive model discriminating significant histological changes in treatment‐naive chronic hepatitis B patients with normal ALT. Virol J. 2023;20(1):7. doi:10.1186/s12985-023-01963-x.
      Wu XN, Wang MZ, Zhang N, et al. Sex‐determining region Y gene promotes liver fibrosis and accounts for sexual dimorphism in its pathophysiology. J Hepatol. 2024;8. Published online. doi:10.1016/j.jhep.2024.01.036.
      Duan M, Chi X, Xiao H, Liu X, Zhuang H. High‐normal alanine aminotransferase is an indicator for liver histopathology in HBeAg‐negative chronic hepatitis B. Hepatol Int. 2021;15(2):318‐327. doi:10.1007/s12072-021-10153-2.
      Zhan J, Wang J, Zhang Z, et al. Noninvasive diagnosis of significant liver inflammation in patients with chronic hepatitis B in the indeterminate phase. Virulence. 2023;14(1):2268497. doi:10.1080/21505594.2023.2268497.
      Chen L, Zhang XX. Guidelines for the prevention and treatment of chronic hepatitis B (2022 version): re‐discussion of the natural history of the hepatitis B virus infection stage and its connotation. Zhonghua Gan Zang Bing Za Zhi. 2024;32(1):80‐82. doi:10.3760/cma.j.cn501113-20231120-00207.
      Hui CK, Leung N, Yuen ST, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune‐tolerant phase. Hepatology. 2007;46(2):395‐401. doi:10.1002/hep.21724.
      Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130(3):678‐686. doi:10.1053/j.gastro.2005.11.016.
      Zoulim F, Mason WS. Reasons to consider earlier treatment of chronic HBV infections. Gut. 2012;61(3):333‐336. doi:10.1136/gutjnl-2011-300937.
      Lee HW, Chan HLY. Unresolved issues of immune tolerance in chronic hepatitis B. J Gastroenterol. 2020;55(4):383‐389. doi:10.1007/s00535-020-01665-z.
      Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol. 2007;47(6):760‐767. doi:10.1016/j.jhep.2007.07.022.
      Park JY, Park YN, Kim DY, et al. High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels. J Viral Hepat. 2008;15(8):615‐621. doi:10.1111/j.1365-2893.2008.00989.x.
      Chang X, Wang J, Chen Y, et al. A novel nomogram to predict evident histological liver injury in patients with HBeAg‐positive chronic hepatitis B virus infection. EBioMedicine. 2021;67:103389. doi:10.1016/j.ebiom.2021.103389.
      Nguyen MH, Garcia RT, Trinh HN, et al. Histological disease in Asian‐Americans with chronic hepatitis B, high hepatitis B virus DNA, and normal alanine aminotransferase levels. Am J Gastroenterol. 2009;104(9):2206‐2213. doi:10.1038/ajg.2009.248.
      Liao B, Wang Z, Lin S, et al. Significant fibrosis is not rare in Chinese chronic hepatitis B patients with persistent Normal ALT. PLoS One. 2013;8(10):e78672. doi:10.1371/journal.pone.0078672.
      Lee DH, Blomhoff R, Jacobs DR. Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radic Res. 2004;38(6):535‐539. doi:10.1080/10715760410001694026.
      Haring R, Wallaschofski H, Nauck M, Dörr M, Baumeister SE, Völzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma‐glutamyl transpeptidase levels. Hepatology. 2009;50(5):1403‐1411. doi:10.1002/hep.23135.
      Lee HA, Lee HW, Kim IH, et al. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune‐tolerant phase. Aliment Pharmacol Ther. 2020;52(1):196‐204. doi:10.1111/apt.15741.
    • Grant Information:
      This study was supported by the funds for the construction of key medical disciplines in Shenzhen No.SZXK076
    • Contributed Indexing:
      Keywords: HBV DNA; chronic hepatitis B; immune tolerant phase; liver biopsy
    • Accession Number:
      0 (DNA, Viral)
    • Publication Date:
      Date Created: 20240406 Date Completed: 20240611 Latest Revision: 20240611
    • Publication Date:
      20240611
    • Accession Number:
      10.1111/jvh.13940
    • Accession Number:
      38581159